A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumours

Official Title

A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumours

Summary:

The purpose of this study is to investigate BMS-986226 administered alone or in combination with nivolumab or ipilimumab.

Trial Description

Primary Outcome:

  • Incidence of adverse events (AE)
  • Incidence of serious adverse events (SAE)
  • Incidence of AE due to discontinuation
  • Incidence of AE resulting in death
  • Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria
  • Incidence of clinical laboratory test abnormalities graded according to common terminology criteria for adverse events (CTCAE)
Secondary Outcome:
  • Objective response rate (ORR) measure by Clopper-Pearson method
  • Median Duration of Response (mDOR) measured by Kaplan-Meier method
  • Progression Free Survival (PFS) measured by Kaplan-Meier method
  • Maximum observed plasma concentration (Cmax)
  • Time of maximum observed plasma concentration (Tmax)
  • Area under the concentration-time curve from time 0 to the time of the last [AUC (0-T)]
  • Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]
  • Incidence of anti-drug antibodies to BMS-986226 assessed by immunoassay
  • Change from baseline in immunoassay for BMS-986226

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society